DNTH: Dianthus Therapeutics Inc Price to Sales
The lack of operating cash flow and a strategic reliance on R&D investments create a certain developmental inertia for Dianthus Therapeutics (DNTH). The price-to-sales ratio visualizes these consolidation phases, with the current metric standing at 1898.80. The business foundation is based on robotic antibody screening and strict logistical control during the transportation of reagents for clinical trials.
Metric breakdowns and analytics for Dianthus Pharma (DNTH)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Dianthus Therapeutics|DNTH - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Dianthus Corp|DNTH - Company Total Debt|Debt to Book Capital Dianthus Pharma|DNTH - Company Long-Term Debts|Company Short-Term Loans and Borrowings Dianthus Therapeutics|Quick Ratio dianthustx.com
- net income and valuation multiples indicators:
DNTH - Company Net Income|Company Profit Forecast Dianthus Therapeutics|DNTH - Price to Earnings Ratio|Future Price to Earnings Multiple Dianthus Therapeutics Inc|DNTH - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Dianthus Pharma|DNTH - Operating profit EBITDA|Earnings per share for the trailing year Dianthus Therapeutics|DNTH - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months dianthustx.com|DNTH - Earnings per share growth in current year|Expected earnings per share trend next year Dianthus Therapeutics
- issuer revenue and sales details:
Summary company analytics:dianthustx.com
The P/S ratio compares the market value of a business to its generated sales, allowing for the determination of the premium paid per unit of revenue in a fundamental valuation. By analyzing the P/S chart, an investor can diagnose the capitalization stability of Dianthus Therapeutics (DNTH), where the diversification of protein synthesis contracts minimizes raw material risks and ensures stable margins during the development of antibodies for treating rare pathologies.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX (Protagonist Corp) - Market Cap to Revenue Ratio|IMVT: P/S Multiple|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols) - P/S Multiple|P/S Multiple Adaptive Biotech|Price-to-Revenue Ratio Celldex (CLDX)|Aurinia Corp - Market Cap to Revenue Ratio|BioCryst - Market Cap to Revenue|Market Cap to Sales Volume VERA (veratx.com)|Pharvaris - P/S Multiple|Market Capitalization-to-Revenue Ratio ABCL (AbCellera Biologics Inc.)|TRML (Tourmaline Corp) - Market Cap to Revenue|Precigen Corp (PGEN) - P/S Multiple|Price-to-Revenue Ratio Pharming Group N.V.|nektar.com (NKTR) - Price-to-Revenue Coefficient|Market Cap to Revenue UPB (Upstream Bio)|ZBIO (Zenas Bio) - Market Capitalization-to-Revenue Ratio|Immunome Corp - Market Cap to Revenue|Market Cap to Sales Volume GOSS (Gossamer Bio Corp.)|KalVista Pharmaceuticals - P/S Multiple|Market Capitalization-to-Revenue Ratio SEPN (septerna.com)|PVLA: P/S Multiple|Price to Sales Savara Inc (SVRA)|Price-to-Revenue Ratio Rigel Pharmaceuticals Inc|ANAB: Market Capitalization-to-Revenue Ratio|P/S Multiple ATXS|P/S Multiple engene.com (ENGN)|Price-to-Revenue Ratio RAPT Therapeutics RAPT|JBIO (Aerovate Therapeutics, Inc.) - Price-to-Sales Ratio|Aclaris - P/S Multiple|Price to Sales Kyverna Therapeutics, Inc|TLSA (Tiziana Life Sciences) - Market Cap to Revenue|cabalettabio.com (CABA) - P/S Multiple|Market Cap to Revenue VTYX|THTX (Theratechnologies, Inc.) - Market Cap to Sales Volume|P/S Multiple AVTX|Price-to-Revenue Coefficient Eledon Pharmaceuticals, Inc|P/S Multiple AGEN (Agenus)|CLYM - Market Cap to Revenue|ZURA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient aTyr Pharma Inc ATYR|ADAG: P/S Multiple|Market Cap to Revenue Ratio IMA|Price-to-Revenue Ratio Shattuck Labs Inc|Market Cap to Revenue Ratio EQ (Equillium Bio)|Market Cap to Revenue CNTB (Connect Biopharma)|Market Cap to Sales Volume IMUX|P/S Multiple ATRA (Atara Bio)|Market Capitalization-to-Revenue Ratio IFRX|XFOR - Price-to-Revenue Ratio|Price-to-Sales Ratio ACET|CELU: P/S Multiple|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|AKTX (akaritx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Market Cap to Revenue|GeoVax Labs Inc - P/S Multiple|EDSA - P/S Multiple|IBIO (iBio, Inc.) - Market Cap to Revenue|Carisma Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio (BOLT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI: Market Cap to Revenue|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Price to Sales scinai.com SCNI|P/S Multiple CALI|affimed.com - Market Cap to Revenue Ratio|P/S Multiple ALLK (Allakos)|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGM Bio - P/S Multiple|ITOS - P/S Multiple|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TCBP|Market Cap to Revenue THRD
